Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Adenoid Cystic × Epirubicin × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 15 Triple Negative Breast Neoplasms 10 Lymphoma, Large B-Cell, Diffuse 2 Resectable HER2-positive Breast Cancer 1 Pathologic Complete Response 1 Non-Muscle Invasive Bladder Neoplasms 1 Nasopharyngeal Carcinoma 1 Lymphoma, T-Cell, Peripheral 1 Inflammatory Breast Neoplasms 1 HR+/HER2- Breast Cancer 1 Epstein-Barr Virus Infections 1 Congenital Abnormalities 1 Carcinoma, Adenoid Cystic 1 CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction 1

Interventions

pembrolizumab 4 Magnetic Resonance Spectroscopy 3 lenvatinib 2 Specimen Handling 2 Nivolumab 2 Carboplatin 2 regorafenib 1 gallium 68 PSMA-11 1 enfortumab vedotin 1 amivantamab 1 Tablets 1 Surveys and Questionnaires 1 Standard of Care 1 Radiosurgery 1 Pemetrexed 1 Ipilimumab 1 Imatinib Mesylate 1 Glutamate Carboxypeptidase II 1 Etoposide 1 Epirubicin 1 Endoscopic Mucosal Resection 1 Cyclophosphamide 1 Combined Modality Therapy 1 Cisplatin 1 CTLA-4 Antigen 1 Blood Specimen Collection 1 BMS-906024 1 68Ga-DKFZ-PSMA-11 1 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07320508 2026-01-21

EIC-SNACC

Eye & ENT Hospital of Fudan University

Phase 2 Recruiting

Carcinoma, Adenoid Cystic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡